Navigation Links
UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
Date:12/3/2007

ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced new data demonstrating that the investigational drug lacosamide, with the proposed brand name Vimpat(TM), administered as oral, adjunctive therapy, significantly reduced the frequency of seizures and was generally well-tolerated in patients with uncontrolled partial-onset seizures, for up to 5.5 years. The results of the two Phase II trials (Abstracts 3.197 and 3.191) were presented today at the 61st annual meeting of the American Epilepsy Society.

"These findings are encouraging because they show lacosamide significantly reduced seizure frequency in this refractory patient population over a long-term period," said Steve S. Chung, Director of Clinical Epilepsy Research at the Barrow Neurological Institute in Phoenix. "Approximately one third of people with epilepsy are resistant to current antiepileptic drugs. These data show lacosamide's potential to fill an unmet need in this patient population."

The first presentation (SP754) was a double-blind, randomized, parallel-group, placebo-controlled Phase II trial involving 405 patients with refractory partial onset seizures, which were uncontrolled despite treatment with one to three AEDs. The patients were randomized to receive lacosamide 400 mg/day or 600 mg/day (given in 2 doses), or placebo over the 12-week treatment period.

The median reduction in seizure frequency from baseline was significantly greater for lacosamide than placebo: 37.3%, 37.8% and 20.8% for lacosamide 400 mg/day, 600 mg/day, and placebo, respectively. Significantly more patients achieved a 50% or greater reduction in seizure frequency with lacosamide than placebo: 38.3%, 41.2% and 18.3% for lacosamide 400 mg/day, 600 mg/day, and placebo, respectively. Nine subjects who completed the Maintenance Phase were seizure free throughout the entire 12-weeks: 4 of 160 completers in the 400 mg/day group (2.5%) and 5 of 62 completers in the 600 mg/day group (8.1%).

The mos
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... and NEW DELHI, India, July 17 ... and the stock market, Daiichi Sankyo,Company, Limited ... (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between ... the largest,controlling shareholders of Ranbaxy, is binding ...
... ST. LOUIS, July 17 SAFC Supply ... of the Sigma-Aldrich Group (Nasdaq:,SIAL), announced today ... initiative,designed specifically to assist its customers with ... (EU) regulation for chemicals --,Registration, Evaluation, Authorization ...
... of bacteria to produce hydrogen in a bioreactor, with the ... an article in the August issue of Microbiology Today, ... be used to scavenge precious metals from spent automotive catalysts ... , Hydrogen has three times more potential energy by weight ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3Fuel from food waste: bacteria provide power 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... identified a new species of mysterious beaked whale based on ... in the Indian and Pacific Oceans over the past 50 ... toothed whales distantly related to sperm whales, are found in ... throughout the world,s oceans. "They are rarely seen at ...
... This news release is available in ... in the body, for instance, during development, or when neurons establish ... ,wrong turn, will generally cause disease or developmental disorders. The cells ... which they then repel after a short period of contact. Among ...
... NY) When the foe is a disease-causing microbe, identifying ... to kill or disable it. Research to gain this ... The Price Family Foundation. The gift to Albert Einstein ... of Oklahoma funds a research collaboration to investigate the structural ...
Cached Biology News:Researchers discover rare new species of deep-diving whale 2Sociable receptors: In pairs, in groups or in a crowd 2Sociable receptors: In pairs, in groups or in a crowd 3Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 2Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 3
... are supplied as 10X concentrated solutions. REact Buffer ... of the REact buffers and one 250 microl ... four 1 ml vials of REact 1 Buffer ... four 1 ml vials of REact 3 Buffer ...
... Apoptosis Assay Kit #4 detects apoptosis ... in the permeability of cell membranes. This ... and propidium iodide nucleic acid stains. YO-PRO-1 ... of apoptotic cells and labels them with ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Biology Products: